A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
Carcinoma, Hepatocellular
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 82 (final count)
- Started
- May 5, 2022
- Main results expected
- Jul 5, 2025
- Fully finished
- Nov 18, 2025
- Results posted
- Oct 14, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Dose Limiting Toxicities
Measured over: From Day 1 (first dose) untill 6 weeks post first dose
Objective Response Rate (ORR) Assessed by BICR - All Comer Population
Measured over: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Objective Response Rate (ORR) Assessed by BICR - All EHSS No Population
Measured over: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05337137 · record last updated 2026-10-14 · checked 2026-11-09 15:47 UTC